Key genes implicated include WT1, which is associated with syndromic presentations such as WAGR syndrome and CTNNB1, with non-syndromic cases displaying a spectrum of mutations impacting tumor behavior and response to therapy [11]. This evidence concerns the gene CTNNB1 and neoplasm.